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Background/Aims: Impaired responsiveness to clopidogrel is common in patients with type 2 diabetes mellitus (DM). 
The aim of this study was to evaluate the clinical application of a point-of-care assay to detect impaired responsiveness to 
clopidogrel after coronary stent implantation in patients with type 2 DM. 
Methods: We measured P2Y12 reaction units (PRU) with the VerifyNow point-of-care assay in 544 consecutive patients 
undergoing dual or triple (i.e., dual plus cilostazol) anti-platelet therapy after coronary stent implantation. High platelet 
reactivity (HPR) was defined as a PRU value ≥ 240. 
Results: The mean PRU values were 233.5 ± 83.2 and 190.3 ± 85.5 in patients undergoing dual or triple anti-platelet 
therapy, respectively (p < 0.001). Patients with DM manifested higher post treatment PRU values (238.3 ± 82.4 vs. 210.8 
± 86.8, p = 0.001) and a higher frequency of HPR (44.8% vs. 31.0%, p = 0.003) as compared to patients without DM. We 
also found that higher PRU values and a higher frequency of HPR were present in patients with DM who were undergoing 
both triple and dual anti-platelet therapy. However, the higher post-treatment PRU values observed in patients with DM 
decreased with triple anti-platelet therapy (219.4 ± 82.5 vs. 247.9 ± 81.1, p = 0.044).
Conclusions: A point-of-care assay can detect elevated platelet reactivity and impaired responsiveness to clopidogrel in 
patients with type 2 DM. The addition of cilostazol to dual anti-platelet therapy may decrease post-treatment PRU values in 
patients with type 2 DM. (Korean J Intern Med 2011;26:145-152)
Keywords: Cilostazol; Clopidogrel; Diabetes mellitus; Platelet function tests; Point-of-care systems
INTRODUCTION
Patients with type 2 diabetes mellitus (DM) have a 
higher risk of cardiovascular events and death than those 
without DM [1-3]. In addition, type 2 DM is a risk factor 
for stent thrombosis after drug-eluting stent implantation 
[4]. Elevated platelet reactivity, among other mechanisms, 
contributes to the increased risk of atherothrombotic 
complications in patients with type 2 DM [5,6]. Elevated 
platelet reactivity is more frequent in patients with type 
2 DM than in those without DM, even when treated with 
dual anti-platelet therapy, such as aspirin and clopidogrel 
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[7,8]. Cilostazol, a phosphodiesterase III inhibitor, has 
additional inhibitory effects on adenosine diphosphate 
(ADP) P2Y12 receptor-induced platelet aggregation when 
used with dual anti-platelet therapy [9,10]. 
Platelet reactivity traditionally has been measured using 
light transmittance aggregometry; however, problems 
with the clinical application of this method limit its 
routine use. The VerifyNow P2Y12 point-of-care assay 
(Accumetrics, San Diego, CA, USA) enables more simple 
and rapid measurements of platelet reactivity. Recent 
studies have shown that elevated platelet reactivity after 
clopidogrel therapy, as measured by a point-of-care assay, 
was associated with a higher risk of adverse events after 
percutaneous coronary intervention (PCI) [11,12].
The aim of this study was to evaluate the clinical 
application of a point-of-care assay to detect impaired 
clopidogrel responsiveness in patients with type 2 DM 
undergoing dual or triple (dual plus cilostazol) anti-platelet 
therapy after a PCI with stent implantation. In addition, 
the effects of cilostazol on platelet reactivity in patients 




This study was conducted on 544 consecutive patients 
who underwent coronary stent implantation. Patients were 
enrolled in three hospitals (Inje University Busan Paik 
Hospital, Yeungnam University Hospital, and Keimyung 
University Dongsan Hospital) under a PCI registry. 
Patients who had received a loading dose of 300 mg or 
600 mg clopidogrel and 200 mg aspirin at least 12 hours 
prior to the PCI or were on maintenance doses of 75 mg 
clopidogrel and 100 mg aspirin per day for more than 5 
days were included in the study. Patients considered as 
having DM were those taking oral hypoglycemic agents 
or those who needed of insulin for adequate glucose 
control at the time of the PCI. Clinical data, including 
the results of the point-of-care assays, were collected 
prospectively. Exclusion criteria were as follows: 1) an ST   
segment elevation myocardial infarction while undergoing 
primary PCI; 2) a platelet count < 100 × 10
3/μL; 3) a serum 
creatinine > 2 mg/dL, and 4) patients who received peri-
procedural glycoprotein IIb/IIIa inhibitors. The local 
institutional review committees approved this study and 
all patients provided informed consent. 
Medications 
Coronary lesions were treated using standard PCI 
techniques. All patients received a daily maintenance 
dose of 75 mg clopidogrel and 100 mg aspirin. In addition, 
cilostazol, 200 mg daily, was prescribed in some patients. 
The addition of cilostazol was left to the discretion of the 
operators. Stent type selection and the use of glycoprotein 
IIb/IIIa antagonists were also left to the discretion of 
the operators. All patients received heparin during the 
procedure to maintain an activated clotting time ≥ 250 
seconds and were prescribed lifelong aspirin. 
Point-of-care assay 
Venous blood was taken from each patient at least 2 
days after the PCI and blood was drawn into a Greiner 
Bio-One 3.2% citrate Vacuette tube
® (Greiner Bio-One, 
Monroe, NC, USA) and run within 60 minutes. The 
VerifyNow P2Y12 assay is a turbidmetry-based optical 
detection device that measures platelet responsiveness 
to clopidogrel and other P2Y12 antagonists. This system 
contains fibrinogen-coated polystyrene beads and 
measures changes in light transmission and thus the 
rate of aggregation in whole blood. This device has two 
whole-blood assay channels. One channel contains 20 
μmol/L of ADP as an agonist. This channel also contains 
prostaglandin E1 as a suppressor of intracellular free 
calcium, which reduces the nonspecific contribution of 
ADP binding to P2Y1 receptors. Another separate channel 
contains an iso-thrombin receptor activating protein as an 
agonist. All results are expressed as P2Y12 reaction units 
(PRU). High platelet reactivity (HPR), as assessed by the 
point-of-care assay, was defined as a PRU value ≥ 240 
according to the results of recent studies [11,12].
Statistical analysis
Comparisons were performed using a Student’s t test or 
Mann-Whitney test and a chi-square or Fisher’s exact test. 
A Kolmogorov-Smirnov test was used to test for normality. 
A multivariate logistic regression analysis was performed 
to identify independent predictors of HPR. All statistical 
tests were two-tailed and a p value < 0.05 was considered 
statistically significant. All calculations were performed 
using SPSS version 13 (SPSS Inc., Chicago, IL, USA).  
RESULTS
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consecutive patients in the current analysis. This study 
population included 154 diabetic patients. The baseline 
characteristics of all subjects are listed in Table 1. The 
diabetic group included 18 patients (11.7%) who needed 
insulin for adequate blood glucose control. Patients with 
DM had a higher frequency of hypertension (p = 0.01) 
and a lower level of creatinine clearance (p = 0.01) as 
calculated using the methods of Cockcroft and Gault, 
compared to those without DM. Patients with DM also 
had a longer stent length per lesion (p = 0.01) and a 
greater stent number per patient (p = 0.02) compared to 
those without DM. However, there were no significant 
differences in other coronary risk factors or medications, 
such as lipid lowering agents and anti-platelet agents.
Table 1. Baseline characteristics
Variables DM (n = 154) Non-DM (n = 390) p value
Age, yr 63.5 ± 8.5 63.5 ± 10.4 0.96
Men   96 (62.3) 268 (68.7) 0.16
Hypertension
a    86 (55.8)  166 (42.6) 0.01
Hypercholesterolemia
b   58 (37.7) 143 (36.7) 0.84
Current smoker    44 (28.6) 141 (36.2) 0.11
Body mass index, kg/m
2 24.3 ± 3.3 24.3 ± 3.0 0.90
Previous myocardial infarction   16 (10.4) 36 (9.2) 0.75
Previous PCI    35 (22.7)   82 (21.0) 0.73
Previous CABG    3 (1.9)   7 (1.8) 1.00
Acute coronary syndrome   89 (57.8) 225 (57.7) 1.00
Duration of diabetes, yr 10.4 - -
Medications
Beta blockers   115 (74.7) 292 (74.9) 1.00
Calcium channel blockers   25 (16.2)   91 (23.3) 0.08
ACE inhibitors or ARB 120 (77.9) 291 (74.6) 0.44
Lipid-lowering agents 0.40
CYP 3A4 metabolized   93 (60.4) 251 (64.4)
Non-CYP 3A4 metabolized    21 (13.6) 38 (9.7)
Proton pump inhibitors   17 (11.0) 37 (9.5) 0.63
Triple anti-platelet agents
c   52 (33.8) 136 (34.9) 0.84
Duration of anti-platelet therapy
d, day   6.9 ± 3.9    6.5 ± 5.0 0.32
Left ventricle ejection fraction, %   53.9 ± 12.3   54.7 ± 11.5 0.51
Platelet count, 10
3/μL 249 ± 85 238 ± 61 0.13
Hemoglobin A1C, %    8.2 ± 1.9   5.6 ± 0.6  0.00
Creatinine clearance, mL/min   67.6 ± 22.7    74.0 ± 24.7 0.01
Glycoprotein IIb/IIIa 14 (9.1) 29 (7.4) 0.59
Multivessel intervention   46 (29.9)   93 (23.8) 0.16
Use of drug-eluting stents 150 (97.4)   375 (96.2) 0.61
Total stent length, mm   36.1 ± 19.8    31.1 ± 18.5 0.01
Stents per patient   1.5 ± 0.7    1.4 ± 0.8 0.02
Values are presented as mean ± SD or number (%).
DM, diabetes mellitus; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; ACE, angiotensin converting 
enzyme; ARB, angiotensin receptor blocker; CYP 3A4, cytochrome P450 3A4 isoenzyme. 
aHypertension: blood pressure greater than 140/90 mmHg or medically treated.
bHypercholesterolemia: serum cholesterol greater than 200 mg/dL or medically treated. 
cTriple anti-platelet agents: aspirin, clopidogrel, and cilostazol.
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Post-treatment PRU values were normally distributed 
(one-sample Kolmogorov-Smirnov test, p = 0.23). The 
mean post-treatment PRU values were 233.5 ± 83.2 and 
190.3 ± 85.5 in patients undergoing dual or triple anti-
platelet therapy, respectively (p < 0.001). Patients with 
DM had a higher post-treatment PRU compared to those 
without DM (238. 3 ± 82.4 vs. 210.8 ± 86.8, p = 0.001) 
(Fig. 1). Patients with DM also had a higher frequency of 
HPR compared to those without DM (44.8% vs. 31.0%, p 
= 0.003) (Fig. 2). The percentage of patients included in 
the 4th quartile of post-treatment PRU values was higher 
in patients with DM as compared to those without DM 
(32.5% vs. 23.3%, p = 0.03). Table 2 shows that higher 
post-treatment PRU values were observed in patients 
with DM undergoing both triple and dual anti-platelet 
therapy. The magnitude of the difference in PRU values 
between patients with and without DM was larger in 
patients undergoing triple anti-platelet therapy compared 
to those undergoing dual anti-platelet therapy. In patients 
with DM, the post-treatment PRU value was significantly 
lower in patients undergoing triple anti-platelet therapy 
as compared to those undergoing dual anti-platelet 
therapy (219.4 ± 82.5 vs. 247.9 ± 81.1, p = 0.044). Table 
3 shows that patients with DM had a higher frequency 
of HPR regardless of the type of anti-platelet therapy. 
The frequency of HPR in patients with DM tended to be 
lower in patients undergoing triple anti-platelet therapy as 
compared to those undergoing dual anti-platelet therapy 
(34.6% vs. 50.0%, p = 0.087). DM was found to be a 
significant predictor of HPR in a multivariable analysis 
(odds ratio [OR], 1.76; 95% confidence interval [CI], 1.19 to 
2.62; p = 0.004). In contrast, patients undergoing triple 
anti-platelet therapy (OR, 0.47; 95% CI, 0.31 to 0.70; p = 
0.001) or who were smokers (OR, 0.63; 95% CI, 0.42 to 
0.94; p = 0.022) were less likely to have HPR. 
There was no significant difference in post-treatment 
PRU values (256.2 ± 114.2 vs. 234.6 ± 76.7, p = 0.299) or 
the frequency of HPR (55.6% vs. 42.4%, p = 0.455) based 
on the treatment modality, i.e., either insulin or oral 
hypoglycemic agents. In addition, there was no significant 
difference in post-treatment PRU values (241.3 ± 82.9 vs. 
231.8 ± 81.9, p = 0.504) or the frequency of HPR (46.7% vs. 
40.8%, p = 0.602) based on the status of diabetic control, 
which was based on a hemoglobin level of A1c 7.0. 
DISCUSSION
The current study included a large number of consecutive 
patients recruited from real-world practice. Within this 
study population, a point-of-care assay could detect 
elevated post-treatment platelet reactivity and impaired 
responsiveness to clopidogrel in patients with type 2 DM 
compared to those without DM. The current study shows 
1) higher post-treatment PRU values and 2) a higher 
frequency of HPR in patients with DM compared to 
patients without DM. Furthermore, higher post-treatment 
PRU values and a higher frequency of HPR were observed 
in patients with DM undergoing triple anti-platelet and 
dual anti-platelet therapy. However, the higher post-
treatment PRU values observed in diabetic patients were 
significantly decreased with triple anti-platelet therapy as 
compared to dual anti-platelet therapy. 
Several studies have reported that impaired platelet 






















p = 0.001  
p = 0.003
 
Figure 2. Frequency of high platelet reactivity (HPR) according 
to diabetic status and anti-platelet therapy. The difference 
between diabetes mellitus (DM) and non-DM patients was 











247.9 ± 81.1 219.4 ± 82.5   227.7 ± 83.5  
179.2 ± 84.3
p = 0.044   p = 0.000  
p = 0.001  
Figure 1. Post-treatment P2Y12 reaction units (PRU) values 
according to diabetic status and anti-platelet therapy. The 
difference between diabetes mellitus (DM) and non-DM patients 
was significant (p = 0.001). The lines inside the boxes denote the 
medians. The boxes mark the interval between the 25th and 75th 
percentiles.Yang TH et al. A point-of-care platelet function assay in type 2 DM patients    149
responsiveness to clopidogrel is more frequent in patients 
with type 2 DM [7,8,13]. Insulin normally inhibits platelet 
aggregation via inhibition of the P2Y12 pathway. However, 
patients with type 2 DM show reduced responsiveness 
to insulin, leading to up-regulation of the P2Y12 pathway 
and elevated platelet reactivity, which results in reduced 
responsiveness to anti-platelet therapy [6,8,14]. Reduced 
responsiveness to clopidogrel has been associated with 
adverse outcomes after PCI, including stent thrombosis 
[15-18]. Furthermore, the wide inter-individual variability 
in the inhibitory effects of clopidogrel is well-established 
[19,20]. Therefore, evaluation of individual clopidogrel 
responsiveness has become common in patients 
undergoing PCI, especially in patients with higher risks, 
such as those with DM. 
Several methods have been used to evaluate clopidogrel 
responsiveness to identify patients at a higher risk of 
adverse events [21]. Light transmittance aggregometry 
following several agonist stimuli has been considered the 
gold standard method for platelet function analysis in 
previous studies; however, the routine use of this method 
in clinical practice is difficult because of the need for well-
trained personnel and blood sample centrifugation [22]. 
Vasodilator-stimulated phosphoprotein phosphorylation 
as measured by flow cytometry also has limitations in 
clinical practice, although this method has a higher 
Table 2. Mean PRU and % inhibition values according to diabetic status and anti-platelet therapy
Variables DM (n = 154) Non-DM (n = 390) p value
Overall group 238.3 ± 82.4 210.8 ± 86.8 0.001
PRU 238.3 ± 82.4 210.8 ± 86.8 0.001
% inhibition   25.2 ± 22.2   32.9 ± 26.0 0.002
Dual therapy
a group (n = 356)
PRU          247.9 ± 81.1 (102)           227.7 ± 83.5 (254) 0.036
% inhibition    21.7 ± 20.9   26.8 ± 23.9 0.072
Triple therapy
b group (n = 188)
PRU         219.4 ± 82.5 (52)         179.2 ± 84.3 (136) 0.004
% inhibition    31.0 ± 22.4 43.5 ± 26.1 0.003
p value
c
PRU 0.044 0.000 NA
% inhibition 0.015 0.000 NA
Numbers in parentheses denote the number of patients.
PRU, P2Y12 reaction unit; DM, diabetes mellitus.
aDual therapy: aspirin and clopidogrel.
bTriple therapy: aspirin, clopidogrel, and cilostazol. 
cp value between dual therapy and triple therapy in DM or non-DM patients.
Table 3. Frequency of high platelet reactivity according to diabetic status and anti-platelet therapy
HPR DM (n = 154) Non-DM (n = 390) p value
Overall group 69 (44.8) 121 (31.0) 0.003
Dual therapy group
a 51 (50.0)  94 (37.0) 0.031
Triple therapy group
b 18 (34.6)  27 (19.9) 0.038
p value
c 0.087 0.001 NA
Values are presented as number (%).
HPR, high platelet reactivity; DM, diabetes mellitus; NA, not available.
aDual therapy: aspirin and clopidogrel.
bTriple therapy: aspirin, clopidogrel, and cilostazol. 
cp value between dual therapy and triple therapy in DM or non-DM patients.150    The Korean Journal of Internal Medicine Vol. 26, No. 2, June 2011
specificity as compared with that of aggregometry [22]. 
Recently, efforts have focused on formulating appropriate 
and cost-effective platelet function tests to measure 
platelet reactivity and clopidogrel hyporesponsiveness so 
that anti-platelet therapy can be individualized. A point-
of-care assay specifically measures the inhibitory effects of 
clopidogrel on P2Y12 platelet receptor activation. Point-of-
care assay results have been shown to be closely correlated 
with ADP-induced light transmittance aggregometry [23-
25]. Several studies have shown that post-treatment PRU 
values ≥ 235 or 240, as measured by a point-of-care assay, 
are associated with an increased risk of post-PCI adverse 
events, including cardiac death, myocardial infarction, 
and stent thrombosis [11,12,26]. Our findings show a 
higher frequency of HPR in patients with DM as compared 
to those without DM. These results are consistent with a 
study reported by Price et al. [26], in which the frequency 
of high platelet reactivity (PRU ≥ 235) was significantly 
higher than lower platelet reactivity in patients with DM. 
Similar findings were also reported in a study by Marcucci 
et al. [12], where the frequency of residual platelet 
reactivity (PRU ≥ 240) was significantly higher in patients 
with DM.
The appropriate management of impaired clopidogrel 
responsiveness in drug-eluting stent treatment remains to 
be determined. A high clopidogrel maintenance dose can 
increase platelet inhibition in patients treated with PCI 
[27], including those with DM [28]. Another approach to 
consider might be the addition of a phosphodiesterase III 
inhibitor such as cilostazol to dual anti-platelet therapy. 
One study showed that the addition of cilostazol to dual 
anti-platelet therapy resulted in higher ADP-induced 
platelet inhibition as compared to dual anti-platelet 
therapy alone [9]. Another study showed that additional 
cilostazol reduced the rate of high post-treatment platelet 
reactivity and intensified platelet inhibition as compared to 
a high maintenance dose of clopidogrel (150 mg/day) [29]. 
Previous studies used light transmittance aggregometry 
to demonstrate higher platelet inhibition with triple anti-
platelet therapy as compared to dual anti-platelet therapy 
in the general population [9,29]. In contrast, our findings 
showed that adjunctive cilostazol has additional anti-
platelet effects in patients with type 2 DM as measured 
with a point-of-care assay. 
There was no significant difference in post-treatment 
PRU values or the frequency of HRP depending on the 
type of treatment modality or the status of diabetic control 
(based on a hemoglobin level of A1c 7.0) in the patients 
with DM. Because a smaller number of patients were 
treated with insulin and a greater number of patients 
had relatively good diabetic control in the current study, 
further studies are warranted to examine patients treated 
with insulin as compared to those with uncontrolled DM.
The limitations of the current study include the 
following. First, the current study was based on an analysis 
of registry data; therefore, there were some discrepancies 
in the period of use of the anti-platelet agents from onset 
of anti-platelet therapy to the platelet function test among 
individual patients. However, a relatively large number of 
study subjects were assessed and there was no statistical 
difference in the period of use of anti-platelet agents. 
Second, because the current study was not a randomized 
trial, there may be a selection bias in the analysis of triple 
anti-platelet therapy effects in patients with DM. Third, 
the current study focused on the results of a point-of-care 
assay; therefore, the clinical effects, according differences 
in the degree of platelet inhibition, were not assessed in 
association with the results of the point-of-care assay. 
Additional prospective, randomized studies including 
clinical data are planned at our institution. Finally, the 
mean post-treatment PRU value in patients undergoing 
dual anti-platelet therapy was somewhat higher than that 
reported in two previously published studies [12,26]. One 
study identified a higher prevalence of cytochrome P450 
2C19 genetic polymorphisms in an Oriental population 
as compared with westerners, which could be a possible 
explanation for this discrepancy [30]. 
In conclusion, the results of the current study show 
that a point-of-care assay can detect elevated platelet 
reactivity and impaired responsiveness to clopidogrel in 
type 2 DM patients after coronary stent implantation. The 
addition of cilostazol to dual anti-platelet therapy may 
decrease post-treatment PRU values and the frequency 
of HPR in patients with type 2 DM. Investigation of the 
clinical events associated with impaired responsiveness to 
clopidogrel in patients with DM is warranted.  
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